Cue Biopharma (NASDAQ:CUE) Price Target Cut to $2.00 by Analysts at JMP Securities

Cue Biopharma (NASDAQ:CUE) had its target price decreased by analysts at JMP Securities from $15.00 to $2.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. JMP Securities’ target price would indicate a potential upside of 198.02% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Piper Sandler lowered their target price on shares of Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating on the stock in a report on Friday. Oppenheimer reissued an “outperform” rating and set a $10.00 price objective on shares of Cue Biopharma in a report on Tuesday, April 9th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $8.00 price target on shares of Cue Biopharma in a research report on Tuesday, April 9th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $5.80.

Cue Biopharma Trading Down 4.6 %

CUE traded down $0.03 during trading on Friday, hitting $0.67. The company’s stock had a trading volume of 327,893 shares, compared to its average volume of 321,141. The company has a quick ratio of 2.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $32.64 million, a P/E ratio of -0.64 and a beta of 1.96. The stock’s fifty day moving average price is $1.29 and its 200-day moving average price is $1.83. Cue Biopharma has a twelve month low of $0.67 and a twelve month high of $3.95.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Thursday, May 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.05. The company had revenue of $1.72 million for the quarter, compared to analyst estimates of $0.73 million. Cue Biopharma had a negative net margin of 711.84% and a negative return on equity of 128.30%. Analysts anticipate that Cue Biopharma will post -0.97 EPS for the current year.

Institutional Trading of Cue Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legacy Capital Group California Inc. purchased a new position in shares of Cue Biopharma in the fourth quarter valued at $26,000. Navalign LLC bought a new position in shares of Cue Biopharma during the 4th quarter valued at approximately $66,000. Wedmont Private Capital raised its holdings in Cue Biopharma by 100.0% during the 1st quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock valued at $76,000 after buying an additional 20,000 shares during the period. Finally, Vanguard Group Inc. lifted its position in Cue Biopharma by 7.1% in the first quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock worth $4,316,000 after buying an additional 150,457 shares during the last quarter. 35.04% of the stock is owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.